Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 14/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30087433 | 1.00 | KLKB1 (0.44) | KLKB1NR1H2GRIN2BMEN1KMT2A | |
| SCHEMBL23843065 | 1.00 | KLKB1 (0.44) | KLKB1NR1H2GRIN2BMEN1KMT2A | |
| SCHEMBL26311956 | 0.87 | KLKB1 (0.44) | KLKB1TRPA1 | |
| SCHEMBL29302734 | 0.86 | KLKB1 (0.42) | KLKB1 | |
| SCHEMBL31357699 | 0.83 | KLKB1 (0.34) | KLKB1 | |
| SCHEMBL23753979 | 0.83 | KLKB1 (0.34) | KLKB1 | |
| SCHEMBL31357703 | 0.83 | KLKB1 (0.34) | KLKB1 | |
| SCHEMBL23754045 | 0.83 | KLKB1 (0.34) | KLKB1 | |
| SCHEMBL23769390 | 0.82 | KLKB1 (0.40) | KLKB1TRPA1 | |
| SCHEMBL23769542 | 0.82 | KLKB1 (0.42) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837252-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| US-12091399-B2 | Phenyltetrazole derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-17 | — | — | US | disclosed |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| EP-3863713-B1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-01-25 | — | — | EP | disclosed |
| EP-3863713-B1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| WO-2021160718-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021160718-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-19 | — | — | WO | disclosed |
| EP-3863713-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| WO-2020035540-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885NR1H2 957/4885GRIN2B 2187/4885 |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885NR1H2 957/4885GRIN2B 2187/4885 |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885NR1H2 1022/4885GRIN2B 1781/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885NR1H2 957/4885GRIN2B 2187/4885 |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885NR1H2 957/4885GRIN2B 2187/4885 |
| US-12091399-B2 | Phenyltetrazole derivatives as plasma kallikrein inhibitors | KLKB1, SERPINE1, SERPINB1 | KLKB1 1/4885NR1H2 1588/4885GRIN2B 2704/4885 |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885NR1H2 957/4885GRIN2B 2187/4885 |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885NR1H2 1022/4885GRIN2B 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.